spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Charles River Laboratories Expands Services for Early Discovery Screening

Charles River

Addition of high-throughput technologies and expanded pharmacokinetic services enhances existing support for small molecule drug discovery

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the expansion of its service capabilities in early discovery screening. Charles River is the first contract research organization to offer clients access to Apricot Designs' Dual Arm (ADDA) system for high-throughput absorption, distribution, metabolism, and excretion (HT-ADME) to identify potential lead compounds in North America and Europe. Additionally, the Company has geographically expanded its pharmacokinetic (PK) capabilities at sites central to major pharmaceutical and biotechnology hubs.

Early screening provides important insight into a compound’s underlying biology, and streamlined HT-ADME and PK technologies are essential components to identifying promising candidates early in the drug discovery process.

Addition of Apricot Designs’ ADDA System

The ADDA system is a high-speed autosampler designed for drug discovery that provides ADME discovery scientists with a fast sample delivery platform for liquid chromatography/mass spectrometry (LC/MS). Automated permeability, metabolic stability, and protein binding screening assays can be rapidly turned around with the ADDA system and a single mass spectrometer system, saving critical time in the drug discovery process.

Expansion of Pharmacokinetic Capabilities

In both San Francisco and 's-Hertogenbosch, The Netherlands, Charles River has expanded capabilities and capacity for PK screening, providing for interactive and collaborative relationships aimed at accelerating clients’ discovery programs.

Therapeutic-area-agnostic PK services support drug discovery efforts from the initial PK screening of compounds and lead optimization to late-stage candidate nomination and Investigational New Drug-enabling studies.

Approved Quotes

  •  “In early discovery research, screening is an essential component of any successful program. With access to industry-leading technologies, we’re able to provide our clients strategic guidance, ultimately working toward accelerating their programs.” –Birgit Girshick, Corporate Executive Vice President, Discovery and Safety Assessment, Charles River
  • “The early discovery industry is seeing a marked shift towards a better understanding of the underlying biology of candidate compounds. Both HT-ADME and PK technologies are critical to that understanding, and to developing more successful candidates in early discovery.” –Ian Waddell, PhD Executive Director, Biology, Charles River
  • “The ADDA system, Apricot Designs’ dual arm autosampler was designed with early discovery scientists in mind. It enables seamless integration with LC/MS systems, accelerating the laboratory research process and yielding the best results.” –Felix H. Yiu, Founder and CEO, Apricot Designs, Inc.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

Contacts

Investor Contact:
Susan E. Hardy, 781-222-6190
Corporate Vice President, Investor Relations
susan.hardy@crl.com
or
Media Contact: Amy Cianciaruso, 781-222-6168
Corporate Vice President, Public Relations
amy.cianciaruso@crl.com
phone 1.781.222.6000
web www.criver.com
email 251 Ballardvale St., Wilmington, MA 01887
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Aptus Clinical enters into a global partnership agreement with Artelo Biosciences

We are delighted to announce that Aptus Clinical has entered into an agreement with Artelo Biosciences to provide clinical development support the re-purposing of its high-potency dual cannabinoid agonist ART27.13 in oncology.
More info >>


White Papers

Orthogonal Approaches for the Analysis of Protein Sequence and Post Translational Modifications of a Monoclonal Antibody

RSSL

Monoclonal antibodies are an important class of biopharmaceuticals. They are expressed from living cells and therefore, are subject to complex biochemical pathways. Not all of these pathways are fully understood and many are known to be sensitive to subtle environmental changes during production. These changes may affect the final biopharmaceutical sequence, structure and post-translational modifications. This is in addition to any changes that may occur during subsequent purification. This means that the final product from one batch may be subtly different from another batch. Furthermore, each batch is a heterogeneous mix of similar molecules. Analysis of the degree of batch-tobatch variation, and batch heterogeneity, is therefore, very important to establish in order to be confident that the drug is safe and effective for medicinal use.
More info >>

Industry Events

BioPharm America 2018

5-6 September 2018, Hynes Convention Center

BioPharm America™ is a unique partnering event that forms the nexus of discovery and realization. Startup companies, established biotech and entrepreneurs from academia attend in search of finance, pharma and development partners. The event format highlights innovation and promotes new business relationships by bringing dealmakers from the life science ecosystem together to engage and de-risk the enormous task of drug development.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement